1 Article

Evidence of a causal relationship between genetic tendency to gain muscle mass and uterine leiomyomata

- 4 Eeva Sliz^{1,2}, Jaakko Tyrmi^{1,2}, Nilufer Rahmioglu^{6,7}, Krina T. Zondervan^{6,7}, Christian M.
- 5 Becker⁶, FinnGen, Outi Uimari^{3,4,5}*, Johannes Kettunen^{1,2}*
- 6 ¹ Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Finland
- 7 ² Biocenter Oulu, Oulu, Finland
- 8 ³ Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland
- 9 ⁴ PEDEGO Research Unit, University of Oulu and Oulu University Hospital, Oulu, Finland
- ⁵ Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu,
- 11 Finland
- ⁶ Oxford Endometriosis CaRe Centre, Nuffield Department of Women's and Reproductive
- 13 Health, University of Oxford, UK
- ⁷ Wellcome Centre for Human Genetics, University of Oxford, UK
- 15 *Equal contribution of the last authors
- 16 Address for correspondence:
- 17 Eeva Sliz
- 18 Center For Life Course Health Research
- 19 Faculty of Medicine
- 20 Aapistie 5A
- 21 P.O.Box 5000, 90014 University of Oulu
- 22 Oulu, Finland
- 23 phone: +358 50 305 4865
- 24 e-mail: eeva.sliz@oulu.fi
- 25 Word count Introductory paragraph: 150
- 26 Word count Manuscript main body: 1627
- 27 Figures: 4
- 28 Tables: 1
- 29 Supplementary figures: 63
- 30 Supplementary tables: 9
- 31 References: 68
- 32 Key words: Uterine leiomyoma, GWAS, smooth muscle, muscle mass
- 33 Summary statistics will be made available through the NHGRI-EBI GWAS Catalog with
- 34 GCSTxxxxxx upon publication.

35 Uterine leiomyomata (UL) are the most common benign tumours of the female genital 36 tract with an estimated lifetime incidence of up to $70\%^{1}$. To date, 7 genome-wide association studies (GWASs) have identified 35 loci predisposing to UL. To improve the 37 38 understanding of the underlying genetic pathways, we conducted the largest genetic association study of UL to date in 426,558 European women from FinnGen and a 39 previously published UL meta-GWAS². We identified 36 novel and replicated 31 40 41 previously reported loci. Annotations of the potential candidate genes suggest 42 involvement of smooth muscle cell (SMC) differentiation and/or proliferation-43 regulating genes in modulating UL risk. Our results further advocate that genetic 44 predisposition to increased fat-free mass may be causally related to UL risk, 45 underscoring the involvement of altered muscle tissue biology in UL pathophysiology. 46 Overall, our findings provide novel insights into genetic risk factors related to UL, 47 which may aid in developing novel treatment strategies.

48 UL are hormone-driven benign neoplasms of the uterus composed mostly of SMC and 49 fibroblasts with a profound component of extracellular matrix (ECM). UL are present in 50 single or multiple numbers, with size ranging from millimeters to 20 cm or more in diameter³. In 25-50% of women with ULs, the enlarged and deformed uterus can cause 51 symptoms such as heavy or prolonged menstrual bleeding resulting in anemia, reduced 52 fertility, and pregnancy complications⁴. Major risk factors for UL are family history, African 53 54 ancestry, increasing age up to menopause, and nulliparity⁵. Also, metabolic factors, including hypertension and increased body mass index (BMI), have been reported in association with 55 UL susceptibility⁶. Familial aggregation, twin studies, and disparity in prevalence between 56 different ethnic groups suggest that genetic factors modulate UL risk⁷⁻¹⁰. 57

Until recently, the focus in the genetics of UL has been on somatic rearrangements, and key 58 59 driver variations in MED12, FH, HMGA2 and COL4A6-COL4A5 have been reported¹¹. To add understanding to the heritable genetic underpinnings, we conducted two sets of fixed-60 effect, inverse-variance weighted meta-analyses with data from FinnGen (18,060 cases and 61 105,519 female controls) and 1) a previously published UL meta-GWAS² totaling 53,534 62 cases and 373,024 female controls in 'META-1' and 2) the UK Biobank totaling 33,244 63 cases and 311,271 controls in 'META-2'. META-1 was restricted to publicly available 64 10,000 variants from the previous meta-GWAS², wheras the META-2 included 10,693,588 65 variants across the genome. In META-1, we identified 63 loci associating with UL at 66 $p < 5 \times 10^{-8}$ (Figure 1, Table S1); of these, 32 were novel (Table 1). In META-2, we identified 67 68 51 loci out of which 4 had not been associated with UL risk in prior GWASs or in META-1 69 (Figure 1, Table 1, Table S2). Regional association plots of the novel loci are presented in 70 Figures S1-S36. There was no evidence of inflation in the test statistics (Figure S37). LD 71 score (LDSC) regression-derived SNP-based heritability was estimated to be 0.099 (standard 72 error=0.01) on the liability scale. Characterization of the genome-wide results of META-2 73 suggested that the key UL associated variants were mostly intronic (Figure 2A). Genes 74 associated with UL risk (Figure 2B) were significantly enriched on pathways related to gonad 75 development, positive regulation of growth, and cellular senescence (Figure 2C) and they 76 were mostly expressed in uterus, cervix, and fallopian tube (Figure 2D). In two of the novel 77 loci, we found evidence that altered gene expression mediates UL association (Figures S38-78 S40).

Previous GWAS findings^{2,12-17} have indicated that genetic factors altering pathways involved in estrogen signalling, Wnt signalling, transforming growth factor (TGF)- β signalling, and cell cycle progression are associated with UL risk¹⁸. The novel loci identified in this study further underscore the involvement of pathways regulating SMC proliferation in modulation of UL risk. Many of these pathways are interrelated: for example, both estrogen and

84 progesterone increase the secretion of Wnt ligands from myometrial or leiomyoma SMC, 85 which promotes cell proliferation and tumorigenesis via activation of β -catenin¹⁹. Steroid hormones also influence the production of ECM via signalling through the TGF- β family of 86 ligands and receptors that are highly expressed in multiple fibrotic conditions²⁰⁻²⁶ and 87 contribute to the fibrotic phenotype seen in $UL^{24,25,27-29}$. We identified multiple loci with 88 89 potential candidate genes functioning in one or more of these pathways, and, in the following, 90 we describe some of our key findings with the focus on loci involved in regulation of SMC 91 proliferation.

92 A central finding is the novel association at 17p12 harbouring myocardin (MYOCD; Figure 93 S27). Myocardin is a transcription factor expressed in smooth muscle tissues, including most 94 prominently arteries and colon, but also uterus (Figure S41), and it is required for SMC differentiation³⁰. The expression of myocardin has been shown to be downregulated in UL 95 tissue compared with normal myometrium³¹. Also, it has been proposed that the loss of 96 myocardin function may be a key factor in driving SMC proliferation in UL^{31} ; however, there 97 98 are no reported GWAS associations implicating myocardin until now. The lead variants near 99 MYOCD are intergenic variants with no strong evidence of altered regulatory consequences 100 (Table S3) and, thus, a possible association-driving mechanism remains inconclusive. We 101 identified another myocardin-related novel UL risk association near 'myocardin-induced 102 smooth muscle cell lncRNA, inducer of differentiation' (MYOSLID), a transcriptional target of myocardin³² (Figure S6). RegulomeDB³³ annotation provided robust evidence that the 103 104 association lead variant is a regulatory variant (Table S4) altering binding of multiple 105 transcription factors (Table S5), including Fos proto-oncogene (FOS) that has been shown to be downregulated in UL³⁴. To add yet another example of a myocardin-related UL risk loci, a 106 well-established UL risk association at 22q13.1^{2,12,16,35,36} locates near 'myocardin related 107 108 transcription factor A' (MRTFA; also known as MKL1), a gene interacting with myocardin^{3/}. 109 Also, expression of MRTFA/MKL1 has been shown to be downregulated in UL-related deletions at $22q^{38}$. 110

111 Others have suggested that loss of myocardin function may account for the differentiation 112 defects of human leiomyosarcoma cells during malignant transformation³⁹: downregulation 113 of myocardin resulted in lower expression of cyclin dependent kinase inhibitor 1A 114 (CDKN1A; also known as p21), a mediator of cell cycle G1 phase arrest, which facilitated 115 cell cycle progression. We identified a novel UL association at 6p21.2 near CDKN1A (Figure 116 S13); the association lead variants locate on intergenic region with possible regulatory 117 consequences (Table S6). Previous evidence suggests that CDKN1A is among the genes, the expression of which correlates with UL size⁴⁰. Another novel UL association at 20q13.31 118 119 harbours RNA binding motif protein 38 (RBM38; Figure S29) that specifically binds to and regulates the stability of CDKN1A transcripts³⁷. In this locus, the UL risk-increasing 120 121 rs13039273-C associates with lower *RBM38* expression in ovary ($p=8.7 \times 10^{-6}$)(Table S7, Figure S42; eQTL in uterus $p=2.2 \times 10^{-3}$). Relevant to UL, a variant in the same locus 122 123 (rs760640162) has been previously associated with 'pregnancy examination and test' $(p=5.97 \times 10^{-15})$ in the UK Biobank^{41,42}. Interestingly, estrogen receptor (ER) α has been shown to inhibit expression of myocardin³¹, suggesting that the ability of myocardin-CDKN1A-124 125 126 signalling to inhibit cell cycle progression may be impaired in tissues enriched with ERa. 127 Taken together our findings and previous evidence, it seems highly probable that 128 downregulation of myocardin-CDKN1A signalling increases the risk of UL.

We used an automated LDSC regression pipeline⁴³ to evaluate the genetic correlations (r_g) of UL with other traits (Figure 2; Table S8). The most robustly correlated traits were seen for other gynecological traits, such as bilateral oophorectomy (r_g =0.74, p=1.05x10⁻²⁵), hysterectomy (r_g =0.62, p=3.24x10⁻¹⁹), age at menarche (r_g =-0.18, p=1.40x10⁻⁹), excessive

frequent and irregular menstruation ($r_g=0.51$, $p=5.66 \times 10^{-7}$), having had menopause ($r_g=-0.33$, 133 134 $p=2.31 \times 10^{-5}$), and usage of hormonal replacement therapy ($r_g=0.20$, $p=5.54 \times 10^{-5}$). Strong correlations were also seen between UL and anthropometric and metabolic measures, 135 including whole body fat-free mass ($r_g=0.11$, $p=4.21 \times 10^{-5}$), high blood pressure ($r_g=0.15$, 136 $p=4.58 \times 10^{-6}$), and serum triglyceride level ($r_g=0.16$, $p=4.80 \times 10^{-5}$). Genetic susceptibility for 137 138 UL was also correlated with genetic susceptibility for multiple psychiatric or mood-related 139 traits, including depressive symptoms ($r_g=0.20$, $p=3.31\times10^{-5}$) or neuroticism score ($r_g=0.14$, 140 $p=3.88 \times 10^{-5}$).

141 To estimate the causal relationships between UL and the key traits showing significant r_o 142 with UL, we applied two-sample Mendelian randomization. Our results suggest that genetic tendency to accumulate fat-free mass may be causally linked to higher risk of UL 143 144 $(p=2.37 \times 10^{-3};$ Figure 3; Table S9). In line with this, the higher impedance of whole body (i.e., 145 a bioelectrical measure used for estimating body composition; lower muscle mass leads to 146 higher impedance) was causally associated with a lower risk of UL ($p=1.05 \times 10^{-3}$). When 147 considering the null causal effect of whole-body fat mass on UL risk (p=0.46), it seems 148 apparent that the nominally significant $(p=8.40 \times 10^{-3})$ causal effect of BMI on UL in the present study and the previously reported associations of BMI with UL risk⁴⁴⁻⁴⁶ arise from the 149 150 increased lean body mass rather than fat mass. Although we did not observe horizontal 151 pleiotropy, the causal estimates were heterogenic for many key traits (Table S9), suggesting 152 that all the underlying genetic pathways may not function in a consistent manner – thus, these 153 results need to be interpreted with caution. However, in the leave-one-out sensitivity analyses 154 all causal estimates were consistently positive (higher fat-free mass was causally associated 155 with higher risk of UL) or negative (higher impedance was causally associated with lower 156 risk of UL) suggesting that there is no single variant driving the causal associations (Figures 157 \$50-\$63). Regarding most of the gynecological traits, the causal direction with UL was not 158 clear (Table S9), suggesting that the shared molecular factors predispose to multiple 159 gynecological complications simultaneously instead of one being causal to another. Of note, 160 we replicated the previously reported finding of genetic predisposition to UL being causal to excessive menstrual bleeding² ($p=1.07 \times 10^{-4}$). 161

162 The discovered causal relationship between genetic tendency to accumulate fat-free mass and 163 UL risk provides a novel perspective on UL-related pathophysiology. UL are considered estrogen-dependent, and UL have higher ERa expression compared with normal uterine 164 myometria^{47,48}. ERs are expressed in a variety of tissues, including all musculoskeletal 165 tissues⁴⁹. In females, muscle mass and strength are closely coupled with estrogen status: girls 166 begin to gain muscle mass after the onset of puberty⁵⁰ whereas in older age during 167 perimenopausal and postmenopausal periods, muscle strength declines considerably^{51,52}. If 168 estrogen enhances muscle growth⁵³, the observed causal relationship between fat-free mass 169 170 and UL risk could arise secondary to high estrogen contributing to the muscle growth. Many 171 of the newly identified candidate genes, however, directly regulate cell proliferation – thus, it 172 remains possible that the estrogen-rich environment, due to sexual maturity, may trigger 173 excess SMC growth resulting in ULs in women who are genetically susceptible to build up 174 muscle.

175 Currently, the only essentially curative treatment for UL is hysterectomy, which underscores 176 the high demand for the development of alternative effective therapies. Our findings double 177 the number of known UL risk loci and, thus, the herein presented results provide several 178 potential targets for translational research to develop pharmacologic interventions for UL. 179 Therapies targeted at myocardin-CDKN1A signalling or, considering the causal evidence, 180 other factors regulating muscle growth may hold the greatest potential.

1 Table 1. Novel UL risk loci.

2 The table reports novel distinct loci (more than 1Mb apart) containing at least one variant identified to be associated with UL at $p < 5 \times 10^{-8}$ in a meta-analysis of

3 53,534 UL cases and 373,024 female controls from FinnGen and a previously published meta-GWAS of UL² (META-1) and in a meta-analysis of 33,244 UL

4 cases and 311,271 female controls from FinnGen and the UK Biobank (META-2).

Locus	Chr:Pos (hg38)	Nearest gene(s)	Candidate gene(s)	rsID	EA	EAF	OR (95% CI)	P-value	HetPVal	FIN enr.
Novel loci in META-1										
1q43	1:241860596	EXO1	EXO1, FH	rs4149909	G	0.03	1.13 (1.08-1.18)	1.16E-08	0.265	1.03
1q44	1:244151650	ZBTB18, C1orf100	ZBTB18, AKT3	rs2183478	G	0.18	1.07 (1.05-1.09)	1.75E-11	0.774	1.57
1q44	1:248897507	PGBD2	ZNF692	rs4335411	Α	0.76	1.06 (1.04-1.08)	4.12E-10	0.376	0.98
2p14	2:66863235	MEIS1	MEIS1	rs17631680	С	0.10	0.93 (0.91-0.95)	1.93E-10	0.127	0.96
2q11.2	2:99454113	REV1	REV1	rs13392042	G	0.58	1.05 (1.03-1.06)	4.21E-11	0.217	1.21
2q33.3	2:207258660	MYOSLID, KLF7	MYOSLID	rs10804157	С	0.44	1.04 (1.03-1.05)	1.04E-08	0.143	0.87
2q37.3	2:241720139	ING5	ING5	rs34766121	Т	0.24	1.06 (1.04-1.08)	5.02E-10	0.278	1.03
3p26.1	3:4674530	ITPR1	ITPR1	rs3804984	С	0.38	0.95 (0.93-0.96)	8.06E-15	0.021	1.42
3p24.2	3:24213259	THRB	THRB	rs1010961	А	0.45	1.04 (1.03-1.06)	1.64E-10	0.109	0.98
3q27.2	3:185807411	IGF2BP2	IGF2BP2	rs13060777	G	0.26	1.05 (1.04-1.07)	1.14E-11	0.595	1.10
4q23	4:99031559	METAP1	EIF4E, ADH5	rs1037475	G	0.57	1.04 (1.03-1.05)	8.38E-09	0.707	0.95
5q31.1	5:133099880	HSPA4	HSPA4	rs4367292	Т	0.27	0.96 (0.94-0.97)	2.49E-08	0.882	1.15
6p21.2	6:36653670	CDKN1A	CDKN1A	rs10456443	А	0.20	0.95 (0.93-0.96)	2.67E-10	0.039	0.91
6q21	6:109054915	SESN1	SESN1	rs11153158	С	0.13	0.93 (0.92-0.95)	1.05E-10	0.243	1.19
7p14.3	7:33008785	FKBP9, NT5C3A	NT5C3A, BBS9	rs4723230	Т	0.80	1.05 (1.03-1.07)	4.68E-08	0.946	1.03
7q31.31	7:121132432	CPED1	WNT16	rs12706314	А	0.53	1.04 (1.03-1.06)	2.69E-10	0.777	0.89
7q32.3	7:130935964	LINC-PINT	LINC-PINT	rs35908158	С	0.08	1.08 (1.05-1.10)	1.60E-08	0.883	1.41
8p12	8:30452819	RBPMS	RBPMS	rs13275869	С	0.49	0.96 (0.95-0.97)	8.64E-09	0.520	0.98
8q24.21	8:128506035	LINC00824	LINC00824	rs1516980	С	0.25	0.96 (0.94-0.97)	2.72E-08	0.987	0.76
9q22.2	9:89639982	GADD45G	GADD45G	rs28508285	G	0.09	1.07 (1.04-1.09)	1.49E-08	0.362	1.05
10p12.31	10:21517903	SKIDA1	DNAJC1	rs946711	С	0.33	1.05 (1.03-1.06)	2.96E-10	0.460	0.96
10a23.31	10:88331783	RNLS	RNLS	rs1426619	Т	0.45	1.04 (1.03-1.06)	4.92E-09	0.653	1.09
11q23.2	11:112703765	LOC1053694962	LOC105369496	rs10891420	С	0.42	1.05 (1.03-1.06)	1.38E-10	0.019	1.16
15q23	15:67922458	SKOR1	PIAS1	rs12148374	С	0.44	0.96 (0.95-0.97)	1.37E-09	0.832	1.10
16q12.1	16:50059327	HEATR3	BRD7	rs12599260	A	0.73	1.05 (1.04-1.07)	1.09E-11	0.002	1.08
16q12.1	16:51447685	AC007344.1	AC007344.1	rs66998222	А	0.19	0.94 (0.93-0.96)	7.53E-12	0.345	0.79
17p12	17:12652500	MYOCD	MYOCD	rs12601765	Т	0.30	1.04 (1.03-1.06)	3.08E-08	0.400	1.17
19p12	19:22032639	ZNF257	ZNF257	rs8105767	G	0.30	1.05 (1.03-1.06)	2.63E-09	0.143	1.15
20q13.31	20:57441016	CTCFL	RBM38, BMP7	rs13039273	С	0.46	1.04 (1.03-1.06)	3.08E-09	0.874	1.22
20g13.33	20:63638397	STMN3	SLC2A4RG	rs75691080	Т	0.10	0.92 (0.90-0.95)	7.79E-11	0.044	1.25
21q22.12	21:35072824	RUNX1	RUNX1	rs2834747	G	0.30	0.96 (0.94-0.97)	1.44E-08	0.711	1.17
22q12.3	22:36287509	MYH9. APOL1	MYH9	rs9610482	Т	0.19	1.06 (1.04-1.08)	7.89E-11	0.354	0.94
Novel loci in	META-2	- , -								
2p11.2	2:86458018	KDM3A	KDM3A	rs573520030	Т	0.99	0.62 (0.53-0.74)	3.87E-08	0.918	1.83
4p11	4:49085558	CWH43	OCIAD1	rs538533131	А	0.99	0.53 (0.43-0.65)	2,61E-09	0.002	1.15
10a25.1	10:106821670	SORCS1	SORCS1	rs12247648	Т	0.03	1.26 (1.17-1.36)	3.86E-09	0.825	39.55
Xp11.23	X:46904059	JADE3,RP2	SLC9A7	rs6611312	Т	0.53	1.05 (1.03-1.07)	2,54E-08	0.355	1.07

5 6 7 Chr, chromosome; Pos, position (build 38); EA, effect allele; EAF, effect allele frequency; OR, odds ratio; CI, confidence interval; P, p-value; HetPVal, p-value for heterogeneity; FIN enr, Finnish enrichment (calculated as FIN AF / NFEE AF in the Genome Aggregation Database (gnomAD), where FIN AF is the Finnish allele frequency and NFEE AF is the non-Finnish-non-Estonian European allele frequency). 'Nearest gene(s)' reports the gene closest to the association lead variant. 'Candidate gene(s)' indicates the biologically most relevant gene within 1Mb window around the association lead variant.

8 9

190 Figure 1. A combined Manhattan plot of UL associations in META-1 and META-2.

191 We conducted UL GWAS in FinnGen and, subsequently, two sets of meta-analyses with data from a previously published UL meta-analysis² and the UK Biobank, adding up to 53,534 UL 192 193 cases and 373,024 female controls in META-1 (top) and 33,244 UL cases and 311,271 194 female controls in META-2 (bottom), respectively. Blue color denotes novel UL risk loci 195 identified in META-1, and red color indicates novel loci identified in META-2 that were not 196 associated previously with UL risk in prior GWASs or META-1. Black and grey colours 197 indicate odd and even chromosome numbers, respectively. The red dashed lines correspond 198 to the threshold for genome-wide significance ($p < 5 \times 10^{-8}$).



Figure 2. Variant summary and gene set-based results using summary statistics fromMETA-2.

201 A) The proportions of 'independent genome-wide significant variants' and 'variants in LD 202 with independent significant variants' having corresponding functional annotation. Bars are 203 colored according to -log₂(enrichment) relative to all variants in the reference panel. B) A Manhattan plot of the gene-based test computed by MAGMA⁵⁴. The input variants were 204 mapped to 19,920 protein coding genes and, thus, significance was considered at $p < 2.51 \times 10^{-6}$ 205 (0.05/19,920); only 87 genes with p-values below this threshold are plotted. Blue and red 206 207 colours indicate odd and even chromosome numbers, respectively. C) MAGMA⁵⁴ gene-set 208 enrichment analysis was performed for curated gene sets and GO terms available at MsigDB⁵⁵. The plot shows the results for significantly enriched pathways ($p_{\text{Bonferroni}} < 0.05$). 209 D) Results of MAGMA⁵⁴ tissue expression analysis testing a positive relationship between 210 211 tissue-specific gene expression profiles and disease-gene associations. Tissue-specific geneexpression data were from GTEx (v8)⁵⁶. All data plotted in Figure 2 A-D were produced 212 using FUMA⁵⁷. 213



214 Figure 3. Genetic correlations (rg) of UL with other traits.

The analyses were completed using an automated LD score regression pipeline available at

216 <u>http://ldsc.broadinstitute.org/</u>⁴³. Statistical significance was considered at $p < 6x10^{-5}$ (0.05/830,

217 where 830 is the number of traits tested). The results of traits that showed significant r_g with

218 UL are plotted (more results are provided in Table S8). Traits are named as reported in the

219 LD Hub output.



220 Figure 4. Causal relationships between UL and body composition measures.

221 We estimated causal relationships between UL and the key traits showing significant genetic correlation with UL using two-sample Mendelian randomization implemented in 'TwoSampleMR' R library^{58,59}. Bi-directional causal estimates were obtained by using 222 223 224 summary statistics provided by the MRC Integrative Epidemiology Unit (IEU) GWAS 225 database and UL GWAS results obtained in FinnGen in the present study to extract genetic 226 instruments for other, mostly UKBB-based, traits and UL, respectively. LD pruning was completed using European population reference, threshold of $r^2=0.001$, and clumping 227 window of 10kb. Statistical significance was considered at $p < 3x10^{-3}$ (0.05/19, where 19 is the 228 229 number of traits tested; black diamonds). The plot shows the causal estimates obtained using 230 inverse variance weighted method for key body composition measures (more results are 231 provided in Table S9; the scatter plots for the body composition measures can be found in 232 Figures S43-S49, and the results of the leave-one-out sensitivity analyses are showin in 233



234 Methods

235 *Study populations*

236 **FinnGen** (www.finngen.fi/en) is a public-private partnership project launched in 2017 with 237 an aim to improve human health through genetic research. The project utilizes genome 238 information from a nationwide network of Finnish biobanks that are linked with digital health 239 records from national hospital discharge (available from 1968), death (1969-), cancer (1953-240), and medication reimbursement (1995-) registries using the unique national personal 241 identification codes. Ultimately, the data resource will cover roughly 10% of the Finnish 242 population. We studied data from 123,579 female participants (18,060 UL cases and 105,519 243 female controls) from FinnGen Preparatory Phase Data Freeze 5. UL cases were required to 244 have an entry of ICD-10: D25, ICD-9: 218, or ICD-8: 21899, and participants who had no 245 records of these entries were deemed as controls. The Coordinating Ethics Committee of the 246 Hospital District of Helsinki and Uusimaa (HUS) approved the FinnGen study protocol Nr 247 HUS/990/2017.

248 The FinnGen study is approved by Finnish Institute for Health and Welfare (THL), approval 249 THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, number amendments 250 THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, 251 THL/1721/5.05.00/2019, Digital and population data service agency VRK43431/2017-3, 252 VRK/6909/2018-3, VRK/4415/2019-3 the Social Insurance Institution (KELA) KELA 253 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, and Statistics 254 Finland TK-53-1041-17.

The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 5 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154, Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018, Finnish Clinical Biobank Tampere MH0004, Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001.

FibroGENE is consortium of conventional, population-based and direct-to-consumer cohorts that was assembled to replicate and identify UL risk variants. In the study by Gallagher *et al.*, they studied data from 35,474 UL cases and 267,505 female controls including participants from four population-based cohorts (Women's Genome Health Study, WGHS; Northern Finland Birth Cohort, NFBC; QIMR Berghofer Medical Research Institute, QIMR; the UK Biobank, UKBB) and one direct-to-consumer cohort (23andMe) Detailed descriptions of cohorts and sample selections are available in Supplementary Methods².

269 The UK Biobank is a large national and international health resource following the health 270 and wellbeing of 500,000 male and female volunteer participants, enrolled at ages from 40 to 271 69⁶⁰. The study began in 2006 with the aim to follow the participants for at least 30 years 272 thereafter. Information has been collected from participants during recruitment using 273 questionnaires on socioeconomic status, lifestyle, family history and medical history. 274 Participants have also been followed up for cause-specific morbidity and mortality through 275 linkage to disease registries, death registries, and hospital admission records. For this study, 276 altogether 220,936 women of European ancestry were considered. Based on both hospital-277 linked medical records and self-report (interview with research nurse), women with a history 278 of UL were selected as cases (n=15,184), while controls (n=205,752) had no previous history 279 of UL. Informed consent was obtained from all participants. The UKBB project is approved 280 by the North West Multi-Centre Research Ethics Committee.

281 *Genotyping, imputation, and quality control*

282 In FinnGen, genotyping of the samples was performed using Illumina and Affymetrix arrays 283 (Illumina Inc., San Diego, and Thermo Fisher Scientific, Santa Clara, CA, USA). Sample 284 quality control (QC) was performed to exclude individuals with high genotype missingness 285 (>5%), ambiguous gender, excess heterozygosity (±4SD) and non-Finnish ancestry. 286 Regarding variant QC, all variants with low Hardy-Weinberg equilibrium (HWE) p-value 287 (<1e-6), high missingness (>2%) and minor allele count (MAC)<3 were excluded. Chip 288 genotyped samples were pre-phased with Eagle 2.3.5 with the number of conditioning 289 haplotypes set to 20,000. Genotype imputation was carried out by using the Finnish 290 population-specific SISu v3 reference panel with Beagle 4.1 (version 08Jun17.d8b) as 291 described in the following protocol: dx.doi.org/10.17504/protocols.io.nmndc5e. In post-292 imputation QC, variants with imputation INFO<0.6 were excluded.

In UK Biobank, genotyping of samples was performed either on the Affymetrix UK BiLEVE
 or Affymetrix UK Biobank Axiom array. The UK Biobank genotype data passed centralised

- 295 quality control and was imputed by the UKBB team up to the HRC reference panel⁶¹.
- 296 *GWAS*

The UL GWAS in FinnGen was completed using the Scalable and Accurate Implementation of Generalized (SAIGE) software⁶². The association models were adjusted for age, sex, the first 10 genetic principal components, and genotyping batch, and only variants with minimum allele count of 5 were included in the analysis.

301 Given the extensive relatedness in the UK Biobank data, a linear mixed model (LMM) was 302 utilised for association testing that accounts for population structure and model the related 303 individuals, including genotyping array, age and BMI as covariates as implemented in Bolt-304 LMM V2.3.

305 Meta-analyses

Two sets of fixed-effect, inverse-variance weighted meta-analyses (implemented in METAL⁶³) were performed: the results obtained in FinnGen were meta-analyzed with 1) the top 10,000 most significant variants associating with UL in a published GWAS² (META-1) and 2) UL GWAS results obtained in the UKBB. Statistical significance was considered at the standard genome-wide significance level ($p < 5x10^{-8}$). Genomic inflation factor was estimated using an automated LD score (LDSC) regression pipeline⁴³.

312 Characterization of association signals

We used a web-based platform FUMA⁵⁷ to perform functional annotations of the GWAS 313 results: we completed functional gene mapping and gene-based association and enrichment 314 315 tests using the genome-wide UL associations from META-2 (FinnGen and UKBB) and 316 predefined lead variants as reported in Table S2. FUMA identifies variants showing genome-317 wide significant association ($p < 5 \times 10^{-8}$) with the study trait and, among the significant variants, identifies variants in low LD ($r^2 < 0.6$) as 'independent significant variants' and 318 319 further identifies variants in LD $(r^2>0.6)$ with the 'independent significant variants'; 320 ANNOVAR⁶⁴ annotations are performed for all these variants to obtain information on the functional consequences of the key variants. MAGMA⁵⁴, also implemented in FUMA, was 321 322 used to perform gene-based association testing and gene-set enrichment analyses: gene-based 323 p-values were computed for protein-coding genes by mapping variants to genes and 324 subsequent enrichment analyses were performed for the significant genes using 4728 curated 325 gene sets and 6166 GO terms as reported in MsigDB⁵⁵.

To further characterize the potential UL candidate gene(s) according to biological relevance, we annotated all genes within ± 1 Mb window from the association lead variant. We explored information provided by GenBank³⁷ and UniProt⁶⁵ to determine functions of the genes. To complement the information available in these databases, a broad literature search was performed to identify previous work published regarding to the genes of interest.

331 In each locus, we explored the associations of the lead variant with gene expression levels in 332 the Genotype-Tissue Expression (GTEx) Portal; GTEx was accessed during 02/10/2021-333 02/11/2021. To further test if altered gene expression mediates UL risk associations, we used a method proposed by Zhu et al.⁶⁶ as implemented in Complex Traits Genetics Virtual Lab 334 335 (CTG-VL)⁶⁷; we performed these tests using genome-wide UL results from META-2 and 336 tissue-specific gene expression data (GTEx, V7) for uterus and whole blood. We further used 337 RegulomeDB³³ to discover regulatory elements overlapping with the intergenic variants in 338 the novel loci showing genome-wide significant association with UL risk. Here, significant

- results for the novel loci are reported.
- 340 SNP-based heritability and genetic correlations

The SNP-based heritability (h²_{SNP}) of UL was estimated using LDSC regression implemented 341 in LDSC software⁶⁸. Population prevalence of 0.30 (as in ²) and sample prevalence of 0.11 342 were used to estimate h^2_{SNP} on liability scale. We further applied LDSC to estimate genetic 343 correlation (rg) of UL with other traits using LD Hub⁴³, a web interface for performing 344 345 automated LDSC regression. As recommended, we excluded the major histocompatilibity 346 complex region from the analyses⁴³. We tested r_g between UL and all 830 traits available in 347 the LD Hub database and, thus, statistical significance was considered at $p < 6 \times 10^{-5}$ 348 (0.05/830).

349 Mendelian randomization

350 To test for causal inferences between UL and the key traits showing significant r_g with UL, 351 we performed bi-directional two-sample Mendelian randomization. These analyses were completed using 'TwoSampleMR' R library⁵⁸ (https://mrcieu.github.io/TwoSampleMR/). To 352 353 avoid possible bias from overlapping samples, we extracted genetic instruments for UL from 354 the GWAS results obtained in FinnGen, and for other traits from the GWAS database 355 provided by the MRC Integrative Epidemiology Unit (IEU) available at 356 https://gwas.mrcieu.ac.uk/ and integrated in TwoSampleMR. LD pruning was completed 357 using European population reference, threshold of $r^2=0.001$, and clumping window of 10kb, 358 as set as default in 'clump_data' function; the numbers of SNPs available for the analyses are 359 listed in Table S9. Inverse variance weighted (IVW) method was considered as a primary 360 analysis, and MR Egger estimates were derived in sensitivity analyses: the estimates were 361 required to be to a matching direction with the IVW-estimates and Egger intercepts were 362 evaluated to assess horizontal pleiotropy. Cochran's Q statistics were derived using 363 'mr_heterogeneity' function to test for heterogeneity. To screen for highly influential variants 364 that could drive the association for example due to horizontal pleiotropy, we performed 365 leave-one-out analyses using 'mr_leaveoneout' function. Statistical significance for the causal effects was considered at $p < 3 \times 10^{-3} (0.05/19)$ to correct for 19 traits tested. 366

367 Acknowledgements and funding

The work was supported through The Sigrid Juselius Foundation (JK) and funds from the Academy of Finland [grant numbers 297338 and 307247](JK), Novo Nordisk Foundation [grant number NNF17OC0026062] (JK), and The Finnish Medical Association (OU).

371 The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and 372 UH 4386/31/2016) and eleven industry partners (AbbVie Inc, AstraZeneca UK Ltd, Biogen 373 MA Inc, Celgene Corporation, Celgene International II Sàrl, Genentech Inc, Merck Sharp & 374 Dohme Corp, Pfizer Inc., GlaxoSmithKline, Sanofi, Maze Therapeutics Inc., Janssen Biotech 375 Inc). Following biobanks are acknowledged for delivering biobank samples to Finngen: 376 Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki 377 **Borealis** Biobank (www.helsinginbiopankki.fi), **Biobank** of Northern Finland 378 (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-379 English.aspx), Clinical Finnish Biobank Tampere (www.tays.fi/en-380 US/Research and development/Finnish Clinical Biobank Tampere), Biobank of Eastern 381 Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-382 Service FI/Potilaalle/Biopankki), Finnish Red Cross Blood **Biobank** 383 (www.veripalvelu.fi/verenluovutus/biopankkitoiminta) and Tervevstalo **Biobank** (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/). 384 All Finnish 385 Biobanks are members of BBMRI.fi infrastructure (www.bbmri.fi).

This research has been conducted using data from UK Biobank, a major biomedical database,
 (<u>http://www.ukbiobank.ac.uk/</u>) under project ID 9637 (Gallagher et al., 2019).

388 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the

389 Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI,

NIDA, NIMH, and NINDS. The data used for the analyses described in this manuscript were obtained from the CTEx Portal on 02/10/2021 02/11/2021

391 obtained from the GTEx Portal on 02/10/2021-02/11/2021.

392 Author contributions

OU conceptualized the study. ES, NR, KTZ, CMB, and JK contributed to the analysis plan. ES, JT and NR analyzed data and generated results. ES, JT, NR, KTZ, and OU interpreted the results. ES and OU wrote the original manuscript. JK supervised the study, obtained funding and provided additional study resources. All authors contributed to revising the content of the manuscript and approved the final version.

398 Competing interests

KTZ: Competing financial interests: Scientific collaborations (grant funding) with Bayer AG,
Roche Diagnostics Inc, MDNA Life Sciences, and Evotec. Competing non-financial
interests: Board memberships of the World Endometriosis Society, World Endometriosis
Research Foundation, and research advisory committee member of Wellbeing of Women
UK.

404 CMB: Competing financial interests: Scientific collaborations (grant funding) with Bayer
405 AG, Roche Diagnostics Inc, MDNA Life Sciences, and Evotec. Scientific board Myovant;
406 IDDM Member ObsEva. Competing non-financial interests: Chair ESHRE Endometriosis
407 Guideline Development Group.

408 **References**

- 409 1 Baird, D. D., Dunson, D. B., Hill, M. C., Cousins, D. & Schectman, J. M. High cumulative
 410 incidence of uterine leiomyoma in black and white women: ultrasound evidence. *Am. J.*411 *Obstet. Gynecol.* 188, 100-107 (2003).
- 412 2 Gallagher, C. S. *et al.* Genome-wide association and epidemiological analyses reveal
 413 common genetic origins between uterine leiomyomata and endometriosis. *Nat Commun* 10,
 414 4857, doi:10.1038/s41467-019-12536-4 (2019).
- Abdul Ghaffar, N. A., Ismail, M. P., Nik Mahmood, N. M., Daud, K. & Abu Dzarr, G. A.
 Huge uterine fibroid in a postmenopausal woman associated with polycythaemia: a case
 report. *Maturitas* 60, 177-179, doi:10.1016/j.maturitas.2008.03.013 (2008).
- 418 4 Stewart, E. A. *et al.* Uterine fibroids. *Nat Rev Dis Primers* **2**, 16043, 419 doi:10.1038/nrdp.2016.43 (2016).
- 5 Stewart, E. A., Cookson, C. L., Gandolfo, R. A. & Schulze-Rath, R. Epidemiology of uterine fibroids: a systematic review. *BJOG* **124**, 1501-1512, doi:10.1111/1471-0528.14640 (2017).
- 422 6 Pavone, D., Clemenza, S., Sorbi, F., Fambrini, M. & Petraglia, F. Epidemiology and Risk
 423 Factors of Uterine Fibroids. *Best Pract. Res. Clin. Obstet. Gynaecol.* 46, 3-11,
 424 doi:10.1016/j.bpobgyn.2017.09.004 (2018).
- 425 7 Van Voorhis, B. J., Romitti, P. A. & Jones, M. P. Family history as a risk factor for 426 development of uterine leiomyomas. Results of a pilot study. *J. Reprod. Med.* **47**, 663-669 427 (2002).
- 428 8 Luoto, R. *et al.* Heritability and risk factors of uterine fibroids--the Finnish Twin Cohort 429 study. *Maturitas* **37**, 15-26 (2000).
- 430 9 Treloar, S. A., Martin, N. G., Dennerstein, L., Raphael, B. & Heath, A. C. Pathways to
 431 hysterectomy: insights from longitudinal twin research. *Am. J. Obstet. Gynecol.* 167, 82-88,
 432 doi:10.1016/s0002-9378(11)91632-9 (1992).
- 433 10 Wise, L. A. *et al.* African ancestry and genetic risk for uterine leiomyomata. *Am. J.* 434 *Epidemiol.* **176**, 1159-1168, doi:10.1093/aje/kws276 (2012).
- 435 11 Mehine, M., Makinen, N., Heinonen, H. R., Aaltonen, L. A. & Vahteristo, P. Genomics of
 436 uterine leiomyomas: insights from high-throughput sequencing. *Fertil. Steril.* 102, 621-629,
 437 doi:10.1016/j.fertnstert.2014.06.050 (2014).
- 438 12 Cha, P. C. *et al.* A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. *Nat. Genet.* **43**, 447-450, doi:10.1038/ng.805 (2011).
- Eggert, S. L. *et al.* Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata. *Am. J. Hum. Genet.* 91, 621-628, doi:10.1016/j.ajhg.2012.08.009 (2012).
- 443 14 Hellwege, J. N. *et al.* A multi-stage genome-wide association study of uterine fibroids in 444 African Americans. *Hum. Genet.* **136**, 1363-1373, doi:10.1007/s00439-017-1836-1 (2017).
- 445 15 Valimaki, N. *et al.* Genetic predisposition to uterine leiomyoma is determined by loci for 446 genitourinary development and genome stability. *Elife* **7**, doi:10.7554/eLife.37110 (2018).
- Rafnar, T. *et al.* Variants associating with uterine leiomyoma highlight genetic background
 shared by various cancers and hormone-related traits. *Nat Commun* 9, 3636,
 doi:10.1038/s41467-018-05428-6 (2018).
- 450 17 Sakai, K. *et al.* Identification of a novel uterine leiomyoma GWAS locus in a Japanese 451 population. *Sci. Rep.* **10**, 1197, doi:10.1038/s41598-020-58066-8 (2020).
- 452 18 Sepulveda, P. V., Bush, E. D. & Baar, K. Pharmacology of manipulating lean body mass.
 453 *Clin. Exp. Pharmacol. Physiol.* 42, 1-13, doi:10.1111/1440-1681.12320 (2015).

- 454 19 Ono, M. *et al.* Paracrine activation of WNT/beta-catenin pathway in uterine leiomyoma stem
 455 cells promotes tumor growth. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 17053-17058,
 456 doi:10.1073/pnas.1313650110 (2013).
- 457 20 Willert, K. & Nusse, R. Wnt proteins. *Cold Spring Harb. Perspect. Biol.* **4**, a007864, doi:10.1101/cshperspect.a007864 (2012).
- 459 21 Borahay, M. A. *et al.* Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and
 460 Therapeutic Implications. *Reprod. Sci.* 24, 1235-1244, doi:10.1177/1933719116678686
 461 (2017).
- 462 22 Massaad-Massade, L. *et al.* HMGA1 enhances the transcriptional activity and binding of the
 463 estrogen receptor to its responsive element. *Biochemistry* 41, 2760-2768,
 464 doi:10.1021/bi011455j (2002).
- 465 23 Dhamad, A. E., Zhou, Z., Zhou, J. & Du, Y. Systematic Proteomic Identification of the Heat
 466 Shock Proteins (Hsp) that Interact with Estrogen Receptor Alpha (ERalpha) and Biochemical
 467 Characterization of the ERalpha-Hsp70 Interaction. *PLoS One* 11, e0160312,
 468 doi:10.1371/journal.pone.0160312 (2016).
- 46924Prossnitz, E. R. et al. Estrogen signaling through the transmembrane G protein-coupled470receptorGPR30.Annu.Rev.Physiol.70,165-190,471doi:10.1146/annurev.physiol.70.113006.100518 (2008).
- 472 25 Ciarmela, P. *et al.* Growth factors and myometrium: biological effects in uterine fibroid and
 473 possible clinical implications. *Hum. Reprod. Update* 17, 772-790,
 474 doi:10.1093/humupd/dmr031 (2011).
- Peng, L. *et al.* Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. *Fertil.* Steril. 91, 2664-2675, doi:10.1016/j.fertnstert.2007.10.083 (2009).
- 478 27 Perrot, V. & Rechler, M. M. The coactivator p300 directly acetylates the forkhead
 479 transcription factor Foxo1 and stimulates Foxo1-induced transcription. *Mol. Endocrinol.* 19, 2283-2298, doi:10.1210/me.2004-0292 (2005).
- 48128Guo, S. *et al.* Phosphorylation of serine 256 by protein kinase B disrupts transactivation by482FKHR and mediates effects of insulin on insulin-like growth factor-binding protein-1483promoter activity through a conserved insulin response sequence. J. Biol. Chem. 274, 17184-48417192, doi:10.1074/jbc.274.24.17184 (1999).
- Lewis, T. D. *et al.* Ulipristal acetate decreases active TGF-beta3 and its canonical signaling in uterine leiomyoma via two novel mechanisms. *Fertil. Steril.* 111, 806-815 e801, doi:10.1016/j.fertnstert.2018.12.026 (2019).
- Chen, J., Kitchen, C. M., Streb, J. W. & Miano, J. M. Myocardin: a component of a molecular switch for smooth muscle differentiation. *J. Mol. Cell. Cardiol.* 34, 1345-1356, doi:10.1006/jmcc.2002.2086 (2002).
- 491 31 Liao, X. H. *et al.* ERalpha inhibited myocardin-induced differentiation in uterine fibroids.
 492 *Exp. Cell Res.* 350, 73-82, doi:10.1016/j.yexcr.2016.11.007 (2017).
- 493 32 Zhao, J. *et al.* MYOSLID Is a Novel Serum Response Factor-Dependent Long Noncoding
 494 RNA That Amplifies the Vascular Smooth Muscle Differentiation Program. *Arterioscler.*495 *Thromb. Vasc. Biol.* 36, 2088-2099, doi:10.1161/ATVBAHA.116.307879 (2016).
- 49633Boyle, A. P. et al. Annotation of functional variation in personal genomes using497RegulomeDB. Genome Res. 22, 1790-1797, doi:10.1101/gr.137323.112 (2012).
- 49834Raimundo, N., Vanharanta, S., Aaltonen, L. A., Hovatta, I. & Suomalainen, A.499Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine500leiomyomas. Oncogene 28, 1261-1273, doi:10.1038/onc.2008.472 (2009).

- 501 35 Edwards, T. L., Hartmann, K. E. & Velez Edwards, D. R. Variants in BET1L and TNRC6B
 502 associate with increasing fibroid volume and fibroid type among European Americans. *Hum.*503 *Genet.* 132, 1361-1369, doi:10.1007/s00439-013-1340-1 (2013).
- 50436Masuda, T. et al. GWAS of five gynecologic diseases and cross-trait analysis in Japanese.505Eur. J. Hum. Genet. 28, 95-107, doi:10.1038/s41431-019-0495-1 (2020).
- 506 37 Clark, K., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J. & Sayers, E. W. GenBank. *Nucleic Acids Res.* 44, D67-72, doi:10.1093/nar/gkv1276 (2016).
- 50838Mehine, M. et al. Integrated data analysis reveals uterine leiomyoma subtypes with distinct509driver pathways and biomarkers. Proc. Natl. Acad. Sci. U. S. A. 113, 1315-1320,510doi:10.1073/pnas.1518752113 (2016).
- 511 39 Kimura, Y., Morita, T., Hayashi, K., Miki, T. & Sobue, K. Myocardin functions as an effective inducer of growth arrest and differentiation in human uterine leiomyosarcoma cells.
 513 *Cancer Res.* 70, 501-511, doi:10.1158/0008-5472.CAN-09-1469 (2010).
- 51440Markowski, D. N. et al. HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in515the growth of uterine leiomyomas. Genes Chromosomes Cancer 49, 661-668,516doi:10.1002/gcc.20777 (2010).
- 517 41 Staley, J. R. *et al.* PhenoScanner: a database of human genotype-phenotype associations.
 518 *Bioinformatics* 32, 3207-3209, doi:10.1093/bioinformatics/btw373 (2016).
- Kamat, M. A. *et al.* PhenoScanner V2: an expanded tool for searching human genotypephenotype associations. *Bioinformatics* 35, 4851-4853, doi:10.1093/bioinformatics/btz469
 (2019).
- 52243Zheng, J. et al. LD Hub: a centralized database and web interface to perform LD score523regression that maximizes the potential of summary level GWAS data for SNP heritability524and genetic correlation analysis.Bioinformatics525doi:10.1093/bioinformatics/btw613 (2017).
- Marshall, L. M. *et al.* Risk of uterine leiomyomata among premenopausal women in relation
 to body size and cigarette smoking. *Epidemiology* 9, 511-517 (1998).
- 528 45 Wise, L. A. *et al.* Influence of body size and body fat distribution on risk of uterine 529 leiomyomata in U.S. black women. *Epidemiology* **16**, 346-354 (2005).
- 530
 46
 Lee, J. E. *et al.* Weight change and risk of uterine leiomyomas: Korea Nurses' Health Study.

 531
 Curr. Med. Res. Opin. **34**, 1913-1919, doi:10.1080/03007995.2018.1462783 (2018).
- 53247Bakas, P. et al. Estrogen receptor alpha and beta in uterine fibroids: a basis for altered533estrogen responsiveness. Fertil. Steril. 90, 1878-1885, doi:10.1016/j.fertnstert.2007.09.019534(2008).
- 53548Valladares, F. *et al.* Characterization of estrogen receptors alpha and beta in uterine536leiomyoma cells. *Fertil. Steril.* **86**, 1736-1743, doi:10.1016/j.fertnstert.2006.05.047 (2006).
- Sipila, S. & Poutamo, J. Muscle performance, sex hormones and training in peri-menopausal and post-menopausal women. *Scand. J. Med. Sci. Sports* 13, 19-25, doi:10.1034/j.1600-0838.2003.20210.x (2003).
- 54050Wood, C. L., Lane, L. C. & Cheetham, T. Puberty: Normal physiology (brief overview). Best541Pract. Res. Clin. Endocrinol. Metab. 33, 101265, doi:10.1016/j.beem.2019.03.001 (2019).
- 542 51 Barros, R. P. & Gustafsson, J. A. Estrogen receptors and the metabolic network. *Cell Metab*543 14, 289-299, doi:10.1016/j.cmet.2011.08.005 (2011).
- 544 52 Chidi-Ogbolu, N. & Baar, K. Effect of Estrogen on Musculoskeletal Performance and Injury 545 Risk. *Front. Physiol.* **9**, 1834, doi:10.3389/fphys.2018.01834 (2018).

- 546 53 Velders, M. & Diel, P. How sex hormones promote skeletal muscle regeneration. *Sports Med.*547 43, 1089-1100, doi:10.1007/s40279-013-0081-6 (2013).
- 54854de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set549analysis of GWAS data. PLoS Comput. Biol. 11, e1004219,550doi:10.1371/journal.pcbi.1004219 (2015).
- 551 55 Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics* **27**, 1739-552 1740, doi:10.1093/bioinformatics/btr260 (2011).
- 553 56 Consortium, G. T. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580-585, doi:10.1038/ng.2653 (2013).
- Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
 annotation of genetic associations with FUMA. *Nat Commun* 8, 1826, doi:10.1038/s41467017-01261-5 (2017).
- 558 58 Hemani, G. *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *Elife* **7**, doi:10.7554/eLife.34408 (2018).
- Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS genetics* 13, e1007081, doi:10.1371/journal.pgen.1007081 (2017).
- 563 60 Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide 564 range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779, 565 doi:10.1371/journal.pmed.1001779 (2015).
- 56661Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature*567562, 203-209, doi:10.1038/s41586-018-0579-z (2018).
- 568 62 Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in
 569 large-scale genetic association studies. *Nat. Genet.* 50, 1335-1341, doi:10.1038/s41588-018570 0184-y (2018).
- Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 26, 2190-2191, doi:10.1093/bioinformatics/btq340 (2010).
- Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants
 from high-throughput sequencing data. *Nucleic Acids Res.* 38, e164, doi:10.1093/nar/gkq603
 (2010).
- 577 65 UniProt, C. UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res.* **47**, D506-578 D515, doi:10.1093/nar/gky1049 (2019).
- 579 66 Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48**, 481-487, doi:10.1038/ng.3538 (2016).
- 58167Cuéllar-Partida, G. *et al.* Complex-Traits Genetics Virtual Lab: A community-driven web582platform for post-GWAS analyses. *bioRxiv*, 518027, doi:10.1101/518027 (2019).
- 583 68 Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity 584 in genome-wide association studies. *Nat. Genet.* **47**, 291-295, doi:10.1038/ng.3211 (2015).
- 585 586

587 **Contributors of FinnGen** 588 **Steering Committee** 589 590 Aarno Palotie Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Mark Daly Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland 591 592 593 Pharmaceutical companies Bridget Riley-Gills Abbvie, Chicago, IL, United States 594 Howard Jacob Abbvie, Chicago, IL, United States 595 Astra Zeneca, Cambridge, United Kingdom Dirk Paul 596 Heiko Runz Biogen, Cambridge, MA, United States 597 Sally John Biogen, Cambridge, MA, United States 598 Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States Robert Plenge 599 Joseph Maranville Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States 600 Mark McCarthy Genentech, San Francisco, CA, United States Genentech, San Francisco, CA, United States 601 Julie Hunkapiller 602 Meg Ehm GlaxoSmithKline, Brentford, United Kingdom 603 Kirsi Auro GlaxoSmithKline, Brentford, United Kingdom 604 Merck, Kenilworth, NJ, United States Simonne Longerich 605 Merck, Kenilworth, NJ, United States Caroline Fox 606 Anders Mälarstig Pfizer, New York, NY, United States 607 Sanofi, Paris, France Katherine Klinger 608 Deepak Raipal Sanofi, Paris, France 609 Eric Green Maze Therapeutics, San Francisco, CA, United States 610 Robert Graham Maze Therapeutics, San Francisco, CA, United States 611 Robert Yang Janssen Biotech, Beerse, Belgium 612 Chris O'Donnell Novartis, Basel, Switzerland 613 614 University of Helsinki & Biobanks 615 Tomi Mäkelä HiLIFE. University of Helsinki, Finland, Finland 616 Jaakko Kaprio Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland, Finland 617 Petri Virolainen Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland 618 Antti Hakanen Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland 619 Terhi Kilpi THL Biobank / The National Institute of Health and Welfare Helsinki, Finland 620 621 622 623 624 Markus Perola THL Biobank / The National Institute of Health and Welfare Helsinki, Finland Jukka Partanen Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank, Helsinki, Finland Anne Pitkäranta Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa, Helsinki 625 Juhani Junttila Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital 625 626 627 628 629 630 District, Oulu, Finland Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital Raisa Serpi District, Oulu, Finland Tarja Laitinen Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District, Tampere, Finland 631 Veli-Matti Kosma Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District, 632 633 Kuopio, Finland Urho Kujala Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District, 634 Jyväskylä, Finland 635 636 Marco Hautalahti FINBB - Finnish biobank cooperative 637 **Other Experts/ Non-Voting Members** 638 Outi Tuovila Business Finland, Helsinki, Finland 639 Raimo Pakkanen Business Finland, Helsinki, Finland 640 641 **Scientific Committee** 642 Pharmaceutical companies 643 Jeffrey Waring Abbvie, Chicago, IL, United States 644 Bridget Riley-Gillis Abbvie, Chicago, IL, United States 645 Ioanna Tachmazidou Astra Zeneca, Cambridge, United Kingdom 646 Chia-Yen Chen Biogen, Cambridge, MA, United States 647 Biogen, Cambridge, MA, United States Heiko Runz 648 Shameek Biswas Celgene, Summit, NJ, United States/Bristol Myers Squibb, New York, NY, United States 649 Sarah Pendergrass Genentech, San Francisco, CA, United States 650 Julie Hunkapiller Genentech, San Francisco, CA, United States 651 Meg Ehm GlaxoSmithKline, Brentford, United Kingdom 652 David Pulford GlaxoSmithKline, Brentford, United Kingdom 653 Neha Raghavan Merck, Kenilworth, NJ, United States

6 F A		
654	Adriana Huertas-Vazquez	Merck, Kenilworth, NJ, United States
622	Jae-Hoon Sul	Merck, Kenilworth, NJ, United States
656	Anders Mälarstig	Pfizer, New York, NY, United States
657	Xinli Hu	Pfizer, New York, NY, United States
658	Katherine Klinger	Sanofi, Paris, France
659	Matthias Gossel	Sanofi, Paris, France
660	Robert Graham	Maze Therapeutics, San Francisco, CA, United States
661	Eric Green	Maze Therapeutics, San Francisco, CA, United States
662	Sahar Mozaffari	Maze Therapeutics, San Francisco, CA, United States
663	Dawn Waterworth	Janssen Research & Development LLC Spring House PA United States
664	Nicole Renaud	Novartis Basel Switzerland
665	Ma´an Obeidat	Novaris, Dasci, Switzerland
666	Wa ch Obeldat	Novartis, Dasci, Switzerland
667	University of Helsinki & D	linhamba
669		
660	Samuli Ripatti	Institute for Molecular Medicine Finland, HILIFE, Helsinki, Finland
009	Johanna Schleutker	Auria Biobank / Univ. of Turku / Hospital District of Southwest Finland, Turku, Finland
6/0	Markus Perola	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
6/1	Mikko Arvas	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank,
672	Helsinki, Finland	
673	Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
674	Helsinki	
675	Reetta Hinttala	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
676	District, Oulu, Finland	
677	Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
678	District Oulu Finland	
679	Arto Mannermaa	Biobank of Fastern Finland / University of Fastern Finland / Northern Savo Hospital District
680	Kuopio Einland	biobank of Eastern Finland / Oniversity of Eastern Finland / Northern Savo Hospital District,
681	Kuopio, Filianu Katriira Aalta Satälä	Einsich Clinical Dickarl, Tennens / University of Tennens / Dickarness Hagridal District
601	Katrina Aato-Setaia	Finnish Chinical Biobank Tampere / University of Tampere / Pirkaninaa Hospital District,
002	Tampere, Finland	
083	Jari Laukkanen	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
684	Jyväskylä, Finland	
685	Urho Kujala	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
686	Jyväskylä, Finland	
687	Johanna Mäkelä	FINBB - Finnish biobank cooperative
688		
689	Clinical Groups	
690	Neurology Group	
691	Reetta Kälviäinen	Northern Savo Hospital District, Kuopio, Finland
692	Valtteri Iulkunen	Northern Savo Hospital District Kuopio Finland
693	Hilkka Sojninen	Northern Savo Hospital District, Kuopio, Finland
69/	Anna Domos	Northern Octrobothnia Hocnitel District, Ouly Finland
605	Allie Kelles	Northern Serie Hearitel District Kuenie, Einland
606		Northern Savo Hospital District, Kuopio, Filinand
090	Jukka Peltola	Pirkanmaa Hospital District, Tampere, Finland
69/	Minna Raivio	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
698	Pentti Tienari	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
699	Juha Rinne	Hospital District of Southwest Finland, Turku, Finland
700	Roosa Kallionpää	Hospital District of Southwest Finland, Turku, Finland
701	Juulia Partanen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
702	Ali Abbasi	Abbvie, Chicago, IL, United States
703	Adam Ziemann	Abbvie, Chicago, IL, United States
704	Jeffrey Waring	Abbyie, Chicago, IL, United States
705	Sahar Esmaeeli	Abbyie, Chicago, IL, United States
706	Nizar Smaoui	Abbyie Chicago, IL, United States
707	Anne Lehtonen	Abbyie, Chicago, IL, United States
708	Susan Eaton	Biogen Cambridge MA United States
700	Justice Dung	Biogen, Cambridge, MA, United States
709	Heiko Kuliz	Biogen, Cambridge, MA, United States
710	Sanni Landenpera	Biogen, Cambridge, MA, United States
712	Janet van Adelsberg	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
712	Shameek Biswas	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
/15	Julie Hunkapiller	Genentech, San Francisco, CA, United States
/14	Natalie Bowers	Genentech, San Francisco, CA, United States
/15	Edmond Teng	Genentech, San Francisco, CA, United States
716	Sarah Pendergrass	Genentech, San Francisco, CA, United States
717	Fanli Xu	GlaxoSmithKline, Brentford, United Kingdom
718	David Pulford	GlaxoSmithKline, Brentford, United Kingdom
719	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
720	Laura Addis	GlaxoSmithKline, Brentford, United Kingdom
		-

721	John Eicher	GlaxoSmithKline, Brentford, United Kingdom
722	Oinggin S Li	Janssen Research & Development, LLC, Titusville, NJ 08560, United States
723	Karen He	Janssen Research & Development, LLC, Spring House, PA, United States
724	Ekaterina Khramtsova	Janssen Research & Development, LLC, Spring House, PA, United States
725	Bervl Cummings	Maze Therapeutics. San Francisco, CA. United States
726	Neha Raghayan	Merck, Kenilworth, NJ, United States
727	Kari Linden	Pfizer New York NY United States
$7\bar{2}8$	Kuri Eliiden	Thee, new Tork, ner, onlice blaces
729	Gastroenterology Group	
730	Martti Färkkilä	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
731	Jukka Koskela	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
732	Sampa Pikkarainen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
733	Airi Jussila	Pirkanmaa Hospital District Tampere Finland
734	Katri Kaukinan	Pirkanmaa Hospital District, Tampere, Finland
735	Timo Blomster	Northern Ostrobothnia Hospital District, Juliu Finland
736	Mikko Kiviniomi	Northern Save Hespital District, Kuopie, Finland
730	Markky Voutilainon	Hospital District of Southwast Finland Turky, Finland
738	Mort Doly	Inspiral District of Southwest Finland, Furku, Finland
730	Ali Abbasi	Abbying Chicago, II. United States
739	All Addasi	Abbyie, Chicago, IL, United States
740	Granam Heap	Abbyie, Chicago, IL, United States
741	Nizer Smooni	Abbyie, Chicago, IL, United States
742	Fadily Dahiman	Abbyie, Chicago, IL, United States
743		Abbyie, Chicago, IL, United States
744	Anne Lentonen	Abbvie, Unicago, IL, United States
745	Keith Usiskin	Ceigene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
740	Tim Lu	Genentech, San Francisco, CA, United States
747	Natalie Bowers	Genentech, San Francisco, CA, United States
740	Danny On	Genentech, San Francisco, CA, United States
749	Sarah Pendergrass	Genentech, San Francisco, CA, United States
750	Linda McCarthy	GlaxoSmithKline, Brentford, United Kingdom
751	Amy Hart	Janssen Research & Development, LLC, Spring House, PA, United States
152	Meijian Guan	Janssen Research & Development, LLC, Spring House, PA, United States
133	Jason Miller	Merck, Kenilworth, NJ, United States
754	Kirsi Kalpala	Pfizer, New York, NY, United States
133	Melissa Miller	Pfizer, New York, NY, United States
/30	Xinli Hu	Pfizer, New York, NY, United States
151		
/38	Rheumatology Group	
139	Kari Eklund	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
/00	Antti Palomaki	Hospital District of Southwest Finland, Turku, Finland
701	Pia Isomaki	Pirkanmaa Hospital District, Tampere, Finland
762	Laura Pirilä	Hospital District of Southwest Finland, Turku, Finland
/03	Oili Kaipiainen-Seppänen	Northern Savo Hospital District, Kuopio, Finland
/64	Johanna Huhtakangas	Northern Ostrobothnia Hospital District, Oulu, Finland
/65	Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, Helsinki, Finland
/66	Ali Abbasi	Abbvie, Chicago, IL, United States
/6/	Jeffrey Waring	Abbvie, Chicago, IL, United States
/68	Fedik Rahimov	Abbvie, Chicago, IL, United States
/69	Apinya Lertratanakul	Abbvie, Chicago, IL, United States
//0	Nizar Smaoui	Abbvie, Chicago, IL, United States
//1	Anne Lehtonen	Abbvie, Chicago, IL, United States
112	David Close	Astra Zeneca, Cambridge, United Kingdom
773	Marla Hochfeld	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
//4	Natalie Bowers	Genentech, San Francisco, CA, United States
115	Sarah Pendergrass	Genentech, San Francisco, CA, United States
776	Jorge Esparza Gordillo	GlaxoSmithKline, Brentford, United Kingdom
777	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
//8	Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States
779	Fabiana Farias	Merck, Kenilworth, NJ, United States
780	Kirsi Kalpala	Pfizer, New York, NY, United States
781	Nan Bing	Pfizer, New York, NY, United States
782	Xinli Hu	Pfizer, New York, NY, United States
783		
784	Pulmonology Group	
785	Tarja Laitinen	Pirkanmaa Hospital District, Tampere, Finland
	5	1 1 1
786	Margit Pelkonen	Northern Savo Hospital District, Kuopio, Finland

788	Hannu Kankaanranta	Pirkanmaa Hospital District, Tampere, Finland
789	Terttu Harju	Northern Ostrobothnia Hospital District, Oulu, Finland
790	Riitta Lahesmaa	Hospital District of Southwest Finland, Turku, Finland
791	Nizar Smaoui	Abbvie, Chicago, IL, United States
792	Alex Mackay	Astra Zeneca, Cambridge, United Kingdom
793	Glenda Lassi	Astra Zeneca, Cambridge, United Kingdom
794	Susan Eaton Stavan Graanharg	Biogen, Cambridge, MA, United States Colorena Summit NI United States/ Pristel Myore South New York NY United States
796	Hubert Chen	Genentech San Francisco. CA United States
797	Sarah Pendergrass	Genentech, San Francisco, CA, United States
798	Natalie Bowers	Genentech, San Francisco, CA, United States
799	Joanna Betts	GlaxoSmithKline, Brentford, United Kingdom
800	Soumitra Ghosh	GlaxoSmithKline, Brentford, United Kingdom
801	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
802	Rajashree Mishra	GlaxoSmithKline, Brentford, United Kingdom
803	3	
804	Cardiometabolic Disease	s Group
805	Teemu Niiranen	The National Institute of Health and Welfare Helsinki, Finland
806	Felix Vaura	The National Institute of Health and Welfare Helsinki, Finland
807	Veikko Salomaa	The National Institute of Health and Welfare Helsinki, Finland
808	Markus Juonala	Hospital District of Southwest Finland, Turku, Finland
809	Kaj Metsärinne	Hospital District of Southwest Finland, Turku, Finland
810	Mika Kähönen	Pirkanmaa Hospital District, Tampere, Finland
811	Juhani Junttila	Northern Ostrobothnia Hospital District, Oulu, Finland
812	Markku Laakso	Northern Savo Hospital District, Kuopio, Finland
813	Jussi Pihlajamäki	Northern Savo Hospital District, Kuopio, Finland
014 015	Daniel Gordin	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
01J 916	Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
817	Tiinamaiia Tuomi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
818	Innanaija Tuonii Jori Loukkonon	Control Finland Health Care District, Jurischuld, Finland
819	Amanda Elliott	Institute for Molecular Medicine Finland Hill IEE University of Helsinki Finland / Broad
820	Institute Cambridge MA	United States
821	Joel Rämö	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
822	Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
823	Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
824	Sanni Ruotsalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
825	Benjamin Challis	Astra Zeneca, Cambridge, United Kingdom
826	Dirk Paul	Astra Zeneca, Cambridge, United Kingdom
827	Keith Usiskin	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
828	Julie Hunkapiller	Genentech, San Francisco, CA, United States
829	Natalie Bowers	Genentech, San Francisco, CA, United States
830	Sarah Pendergrass	Genentech, San Francisco, CA, United States
831	Audrey Chu	GlaxoSmithKline, Brentford, United Kingdom
832	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
833	Dermot Reilly	Janssen Research & Development, LLC, Boston, MA, United States
034 925	Jaakko Parkkinen	Pfizer, New York, NY, United States
836	Nielissa Miller	Prizer, New York, NY, United States
830	Russell Miller	riizer, new Tork, NT, Olineu States
838	Oncology Group	
839	Tuomo Meretoia	Hospital District of Helsinki and Uusimaa Helsinki Finland
840	Heikki Joensuu	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
841	Olli Carpén	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
842	Lauri Aaltonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
843	Johanna Mattson	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
844	Annika Auranen	Pirkanmaa Hospital District, Tampere, Finland
845	Peeter Karihtala	Northern Ostrobothnia Hospital District, Oulu, Finland
846	Saila Kauppila	Northern Ostrobothnia Hospital District, Oulu, Finland
847	Päivi Auvinen	Northern Savo Hospital District, Kuopio, Finland
848	Klaus Elenius	Hospital District of Southwest Finland, Turku, Finland
849	Johanna Schleutker	Hospital District of Southwest Finland, Turku, Finland
850	Esa Pitkänen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
851	Nina Mars	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
032 852	Mark Daly	Institute for Molecular Medicine Finland, HiLlFE, University of Helsinki, Finland
0JJ 854	Kelja Popović	Abbyie, Chicago, IL, United States
054	Jenney waring	Abovie, Chicago, IL, United States

855	Bridget Riley-Gillis	Abbvie, Chicago, IL, United States
856	Anne Lehtonen	Abbvie, Chicago, IL, United States
857	Jennifer Schutzman	Genentech, San Francisco, CA, United States
858	Julie Hunkapiller	Genentech, San Francisco, CA, United States
859	Natalie Bowers	Genentech, San Francisco, CA, United States
860	Sarah Pendergrass	Genentech, San Francisco, CA, United States
861	Diptee Kulkarni	GlaxoSmithKline, Brentford, United Kingdom
862	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
863	Alessandro Porello	Janssen Research & Development, LLC, Spring House, PA, United States
864	Andrey Loboda	Merck, Kenilworth, NJ, United States
865	Heli Lehtonen	Pfizer, New York, NY, United States
866	Stefan McDonough	Pfizer, New York, NY, United States
867	Marika Crohns	Sanofi, Paris, France
868	Sauli Vuoti	Sanofi, Paris, France
869		
870	Opthalmology Group	
871	Kai Kaarniranta	Northern Savo Hospital District, Kuopio, Finland
872	Joni A Turunen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
873	Terhi Ollila	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
874	Sanna Seitsonen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
875	Hannu Uusitalo	Pirkanmaa Hospital District, Tampere, Finland
876	Vesa Aaltonen	Hospital District of Southwest Finland, Turku, Finland
877	Hannele Uusitalo-Järvinen	Pirkanmaa Hospital District, Tampere, Finland
878	Marja Luodonpää	Northern Ostrobothnia Hospital District, Oulu, Finland
879	Nina Hautala	Northern Ostrobothnia Hospital District, Oulu, Finland
880	Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
881	Esa Pitkänen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
882	Mengzhen Liu	Abbvie, Chicago, IL, United States
883	Heiko Runz	Biogen, Cambridge, MA, United States
884	Stephanie Loomis	Biogen, Cambridge, MA, United States
885	Erich Strauss	Genentech, San Francisco, CA, United States
886	Natalie Bowers	Genentech, San Francisco, CA, United States
887	Hao Chen	Genentech, San Francisco, CA, United States
888	Sarah Pendergrass	Genentech, San Francisco, CA, United States
889		
890	Dermatology Group	
891	Kaisa Tasanen	Northern Ostrobothnia Hospital District, Oulu, Finland
892	Laura Huilaja	Northern Ostrobothnia Hospital District, Oulu, Finland
893	Katariina Hannula-Jouppi	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
894	Teea Salmi	Pirkanmaa Hospital District, Tampere, Finland
895	Sirkku Peltonen	Hospital District of Southwest Finland, Turku, Finland
896	Leena Koulu	Hospital District of Southwest Finland, Turku, Finland
897	Nizar Smaoui	Abbvie, Chicago, IL, United States
898	Fedik Rahimov	Abbvie, Chicago, IL, United States
899	Anne Lehtonen	Abbvie, Chicago, IL, United States
900	David Choy	Genentech, San Francisco, CA, United States
901	Sarah Pendergrass	Genentech, San Francisco, CA, United States
902	Dawn Waterworth	Janssen Research & Development, LLC, Spring House, PA, United States
903	Kirsi Kalpala	Pfizer, New York, NY, United States
904	Ying Wu	Pfizer, New York, NY, United States
905		
906	Odontology Group	
907	Pirkko Pussinen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
908	Aino Salminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
909	Tuula Salo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
910	David Rice	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
911	Pekka Nieminen	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
912	Ulla Palotie	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
913	Juha Sinisalo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
914	Maria Siponen	Northern Savo Hospital District, Kuopio, Finland
915	Liisa Suominen	Northern Savo Hospital District, Kuopio, Finland
910	Päivi Mäntylä	Northern Savo Hospital District, Kuopio, Finland
91/	Ulvi Gursoy	Hospital District of Southwest Finland, Turku, Finland
918	Vuokko Anttonen	Northern Ostrobothnia Hospital District, Oulu, Finland
919	Kırsı Sıpilä	Northern Ostrobothnia Hospital District, Oulu, Finland
920	Sarah Pendergrass	Genentech, San Francisco, CA, United States
921		

022	Women's Health and Denn	advestion Crown
922	women's Health and Repr	oduction Group
923	Hannele Laivuori	Institute for Molecular Medicine Finland, HILIFE, University of Helsinki, Finland
924	Venla Kurra	Pirkanmaa Hospital District, Tampere, Finland
925	Oskari Heikinheimo	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
926	Ilkka Kalliala	Hospital District of Helsinki and Uusimaa, Helsinki, Finland
927	Laura Kotaniemi-Talonen	Pirkanmaa Hospital District, Tampere, Finland
928	Kari Nieminen	Pirkanmaa Hospital District, Tampere, Finland
929	Päivi Polo	Hospital District of Southwest Finland, Turku, Finland
930	Kaarin Mäkikallio	Hospital District of Southwest Finland, Turku, Finland
931	Eeva Ekholm	Hospital District of Southwest Finland, Turku, Finland
932	Maria Vääräsmäki	Northern Ostrobothnia Hospital District Oulu Finland
<u> 633</u>	Outi Uimari	Northern Ostrobothnia Hospital District, Oulu, Finland
93/	Laura Morin Panunan	Northern Ostrobothnia Hospital District, Oulu, Finland
035	Maria Turnunainan	Northern Serve Hearitel District Kuenia Finland
933	Marjo Tuppurainen	Normern Savo Hospital District, Kuopio, Finland
930	Katja Kivinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
93/	Elisabeth Widen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
938	Taru Tukiainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
939	Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
940	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
941	Liu Aoxing	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
942	Andrea Ganna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
943	Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland
944	Niko Välimäki	University of Helsinki, Helsinki, Finland
945	Lauri Aaltonen	Hospital District of Helsinki and Uusimaa Helsinki Finland
946	Johannes Kettunen	Northern Ostrobothnia Hospital District Oulu Finland
9/7	Mikko Arvos	Finnich Pad Cross Pland Sorriga Halsinki Finland
0/8	Laffray Waring	Abbyin Chicago, II. United States
040	Defiles t Dilass Cillis	Abbyie, Chicago, IL, United States
949	Bridget Riley-Gillis	Abbvie, Chicago, IL, United States
930	Mengzhen Liu	Abbvie, Chicago, IL, United States
951	Sarah Pendergrass	Genentech, San Francisco, CA, United States
952	Janet Kumar	GlaxoSmithKline, Brentford, United Kingdom
953	Kirsi Auro	GlaxoSmithKline, Brentford, United Kingdom
954		
955	FinnGen Analysis working	group
956	Justin Wade Davis	Abbvie, Chicago, IL, United States
957	Bridget Riley-Gillis	Abbyie, Chicago, IL, United States
958	Reza Hammond	Abbyie, Chicago, IL, United States
959	Fedik Rahimov	Abbyie Chicago II United States
960	Sabah Kadri	Abbyie Chicago II. United States
961	Sabar Esmacoli	Abbyia Chicago, IL, United States
062	Mongghon Liu	Abbyie, Chicago, IL, United States
902	Mengzhen Liu	Adovie, Cincago, IL, United States
905	Slave Petrovski	Astra Zeneca, Cambridge, United Kingdom
964	Eleonor Wigmore	Astra Zeneca, Cambridge, United Kingdom
965	Adele Mitchell	Biogen, Cambridge, MA, United States
966	Benjamin Sun	Biogen, Cambridge, MA, United States
967	Ellen Tsai	Biogen, Cambridge, MA, United States
968	Denis Baird	Biogen, Cambridge, MA, United States
969	Paola Bronson	Biogen, Cambridge, MA, United States
970	Ruovu Tian	Biogen, Cambridge, MA, United States
971	Stephanie Loomis	Biogen, Cambridge, MA, United States
972	Yunfeng Huang	Biogen, Cambridge, MA, United States
973	Ioseph Maranville	Celorene Summit NI United States/ Bristol Myers Souibb New York NY United States
974	Shameek Biswas	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
975	Elmutaz Mohammed	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
076	Samia Wadhaman	Celegene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
970	Samir wadnawan	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
9//	Erika Kvikstad	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
9/8	Minal Caliskan	Celgene, Summit, NJ, United States/ Bristol Myers Squibb, New York, NY, United States
9/9	Diana Chang	Genentech, San Francisco, CA, United States
980	Julie Hunkapiller	Genentech, San Francisco, CA, United States
981	Tushar Bhangale	Genentech, San Francisco, CA, United States
982	Natalie Bowers	Genentech, San Francisco, CA, United States
983	Sarah Pendergrass	Genentech, San Francisco, CA, United States
984	Karen S King	GlaxoSmithKline, Brentford, United Kingdom
985	Padhraig Gormlev	GlaxoSmithKline, Brentford, United Kingdom
986	Jimmy Liu	GlaxoSmithKline, Brentford, United Kingdom
987	Karsten Sieber	Janssen Research & Development LLC Spring House PA United States
988	Amy Hart	Janssen Research & Development, LLC, Spring House, PA, United States

989	Meijian Guan	Janssen Research & Development LLC Spring House PA United States
990	Shicheng Guo	Janssen Research & Development, LLC, Spring House, PA, United States
<u>9</u> 91	Beryl Cummings	Maze Therapeutics, San Francisco, CA, United States
992	Matt Brauer	Maze Therapeutics, San Francisco, CA, United States
993	Jason Miller	Merck, Kenilworth, NJ, United States
994	Fabiana Farias	Merck, Kenilworth, NJ, United States
995	Jorge Del-Aguila	Merck, Kenilworth, NJ, United States
996	Kirill Shkura	Merck, Kenilworth, NJ, United States
99/	Victor Neduva	Merck, Kenilworth, NJ, United States
998	Huilei Xu	Novartis, Basel, Switzerland
1000	Amy Cole	Novartis, Basel, Switzerland
1000	Jaison Jacob	Novatus, Dasel, Switzerland
1002	Katrina de Lange	Novartis, Basel, Switzerland
1003	Jonas Zierer	Novartis, Basel, Switzerland
1004	Xing Chen	Pfizer, New York, NY, United States
1005	Åsa Hedman	Pfizer, New York, NY, United States
1006	Clarence Wang	Sanofi, Paris, France
1007	Ethan Xu	Sanofi, Paris, France
1008	Franck Auge	Sanofi, Paris, France
1009	Clement Chatelain	Sanofi, Paris, France
1010	Deepak Rajpal	Sanofi, Paris, France
1011	Dongyu Liu Kathaning Call	Sanofi, Paris, France
1012	Katherine Call	Sanofi, Paris, France
1013	I al-fie Ala Mitia Kurki	Sanon, Paris, France Institute for Molecular Medicine Finland, HillIFE, University of Helsinki, Finland / Broad
1015	Institute Cambridge MA II	Institute for Wolceural Wedienie Finland, filen E, Oniversity of Heisniki, Finland / Broad
1016	Samuli Ripatti	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1017	Mark Daly	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1018	Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1019	Aki Havulinna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1020	Juha Mehtonen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1021	Priit Palta	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1022	Shabbeer Hassan	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1023	Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1024	Wei Zhou	Broad Institute, Cambridge, MA, United States
1023	Mutaamba Maasha	Broad Institute, Cambridge, MA, United States
1020	Shabbeer Hassan	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1028	Manuel Rivas	University of Stanford Stanford CA United States
1029	Aarno Palotie	Institute for Molecular Medicine Finland Hil IFE University of Helsinki Finland
1030	Arto Lehisto	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1031	Andrea Ganna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1032	Vincent Llorens	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1033	Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1034	Mari E Niemi	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1035	Taru Tukiainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1036	Mary Pat Reeve	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1037	Henrike Heyne	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1030	Nina Mars Kimmo Bolin	Institute for Molecular Medicine Finland, HILIFE, University of Helsinki, Finland
1039	Iavier Garcia-Tabuenca	University of Tampere, Tampere, Finland
1040	Harri Siirtola	University of Tampere, Tampere, Finland
1042	Tuomo Kiiskinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1043	Jiwoo Lee	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1044	Institute, Cambridge, MA, U	Inited States
1045	Kristin Tsuo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1046	Institute, Cambridge, MA, U	Inited States
1047	Amanda Elliott	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1048	Institute, Cambridge, MA, U	Inited States
1049	Kati Kristiansson	I HL BIODANK / I Ne National Institute of Health and Welfare Helsinki, Finland
1050	WIIKKO ArVas Helsinki Einland	FILINSI Red Cross Blood Service / Finnish Hematology Registry and Clinical Blobank,
1052	Kati Hyvärinen	Finnish Red Cross Blood Service, Helsinki, Finland
1053	Jarmo Ritari	Finnish Red Cross Blood Service, Helsinki, Finland
1054	Miika Koskinen	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa.
1055	Helsinki	

1056		
1056	Olli Carpén	Helsinki Biobank / Helsinki University and Hospital District of Helsinki and Uusimaa,
1057	Helsinki	
1058	Johannes Kettunen	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
1059	District, Oulu, Finland	
1060	Katri Pylkäs	University of Oulu, Oulu, Finland
1061	Eeva Sliz	University of Oulu, Oulu, Finland
1062	Minna Karjalainen	University of Oulu, Oulu, Finland
1063	Tuomo Mantere	Northern Finland Biobank Borealis / University of Oulu / Northern Ostrobothnia Hospital
1064	District, Oulu, Finland	
1065	Eeva Kangasniemi	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
1066	Tampere, Finland	
1067	Sami Heikkinen	University of Eastern Finland, Kuopio, Finland
1068	Arto Mannermaa	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
1069	Kuopio, Finland	
1070	Eija Laakkonen	University of Jyväskylä, Jyväskylä, Finland
1071	Dhanaprakash Jambulingam	University of Turku, Turku, Finland
1072	Venkat Subramaniam Rathir	nakannan University of Turku, Turku, Finland
1073	Nina Pitkänen	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland
1074		
1075	Biobank directors	
1076	Lila Kallio	Auria Biobank / University of Turku / Hospital District of Southwest Finland, Turku, Finland
1077	Sirpa Soini	THI, Biobank / The National Institute of Health and Welfare Helsinki, Finland
1078	Jukka Partanen	Finnish Red Cross Blood Service / Finnish Hematology Registry and Clinical Biobank
1079	Helsinki Finland	Thinish Red Closs blood Service / Thinish Heinatology Registry and Chinear Blobank,
1080	Fero Punkka	Helsinki Biohank / Helsinki University and Hospital District of Helsinki and Uusimaa
1081	Lelo Fulkka	neisniki biobalik / neisniki oliiveisity alid nospital bisulet ol neisniki alid ouslilaa,
1081	Deice Comi	Northam Einland Bishard Bonalis / University of Outy / Northam Ostachathais Hearitel
1082	Raisa Seipi District Only Finland	Normeni Finialiu Biobalik Borealis / University of Oulu / Normeni Ostroboullila Hospital
1005	District, Outu, Finiand	Encit Olicial Distant Terror (Heineric of Terror (Distance Herrich Distance
1004	Kimmo Savinainen (acting)	Finnish Clinical Biobank Tampere / University of Tampere / Pirkanmaa Hospital District,
1005	Tampere, Finland	
1080	Veli-Matti Kosma	Biobank of Eastern Finland / University of Eastern Finland / Northern Savo Hospital District,
1087	Kuopio, Finland	
1088	Тещо Киорю	Central Finland Biobank / University of Jyväskylä / Central Finland Health Care District,
1/10/1		
1089	Jyväskylä, Finland	
1089 1090	Jyväskylä, Finland	
1089 1090 1091	Jyväskylä, Finland FinnGen Teams	
1089 1090 1091 1092	Jyväskylä, Finland FinnGen Teams Administration	
1089 1090 1091 1092 1093	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096 1097	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107 \end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109 \end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ \end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop: Hannele Laivuori	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States
1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna Susanna Lemmelä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113 \end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Ment Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113\\ 1114 \end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen L Elisa Lahtela	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Ment Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1000\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113\\ 1114\\ 1115 \end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen L. Elisa Lahtela	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Broad Institute, Cambridge, MA, United States Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113\\ 1114\\ 1115\\ 1116\end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop: Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen L. Elisa Lahtela	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113\\ 1114\\ 1115\\ 1116\\ 1117\\ \end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop: Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen L. Elisa Lahtela Communication	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Ment Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113\\ 1114\\ 1115\\ 1116\\ 1117\\ 1118 \end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen L. Elisa Lahtela Communication Mari Kaunisto	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Ment Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113\\ 1114\\ 1115\\ 1116\\ 1117\\ 1118\\ 1110\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1111\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1117\\ 1118\\ 1110\\ 1111\\ 1110\\ 1111\\ 1110\\ 1111\\ 1110\\ 1111\\ 1110\\ 1111\\ 1110\\ 1110\\ 1111\\ 1110\\ 1110\\ 1111\\ 1110\\ 1100\\ 110\\ 1100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\ 100\\$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen L. Elisa Lahtela Communication Mari Kaunisto E Science	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113\\ 1114\\ 1115\\ 1116\\ 1117\\ 1118\\ 1119\\ 1120\\$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen L. Elisa Lahtela Communication Mari Kaunisto E-Science	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States ment Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113\\ 1114\\ 1115\\ 1116\\ 1117\\ 1118\\ 1119\\ 1120\\ 1121\\$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen L. Elisa Lahtela Communication Mari Kaunisto E-Science Elina Kilpeläinen	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States ment Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
$\begin{array}{c} 1089\\ 1090\\ 1091\\ 1092\\ 1093\\ 1094\\ 1095\\ 1096\\ 1097\\ 1098\\ 1099\\ 1100\\ 1101\\ 1102\\ 1103\\ 1104\\ 1105\\ 1106\\ 1107\\ 1108\\ 1109\\ 1110\\ 1111\\ 1112\\ 1113\\ 1114\\ 1115\\ 1116\\ 1117\\ 1118\\ 1119\\ 1120\\ 1121\\ 1122\end{array}$	Jyväskylä, Finland FinnGen Teams Administration Anu Jalanko Huei-Yi Shen Risto Kajanne Mervi Aavikko Analysis Mitja Kurki Institute, Cambridge, MA, U Juha Karjalainen Pietro Della Briotta Parolo Arto Lehisto Juha Mehtonen Wei Zhou Masahiro Kanai Mutaamba Maasha Clinical Endpoint Develop Hannele Laivuori Aki Havulinna Susanna Lemmelä Tuomo Kiiskinen L. Elisa Lahtela Communication Mari Kaunisto E-Science Elina Kilpeläinen Timo P. Sipilä	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland / Broad Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States Broad Institute, Cambridge, MA, United States ment Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland

11	23 Awaisa Ghazal	Institute for Molecular Medicine Finland, Hil JFE, University of Helsinki, Finland
11	24 Anastasia Shcherh	an Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
11	25	
11	26 Genotyping	
11	27 Kati Donner	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
11	28 Timo P Sipilä	Institute for Molecular Medicine Finland, Hill IFE, University of Helsinki, Finland
11	29 Sample Collectio	n Coordination
11	30 Anu Loukola	Helsinki Biohank / Helsinki University and Hospital District of Helsinki and Uusimaa
11	31 Helsinki	
11	32	
11	33 Sample Logistics	
11	34 Päivi Laiho	THL Biobank / The National Institute of Health and Welfare Helsinki, Finland
11	35 Tuuli Sistonen	THI, Biobank / The National Institute of Health and Welfare Helsinki Finland
11	36 Essi Kaihariu	THE Biohank / The National Institute of Health and Welfare Helsinki, Finland
11	37 Markku Laukkane	n THI Biohank / The National Institute of Health and Welfare Helsinki, Finland
11	38 Elina Järvensivu	THE Biobank / The National Institute of Health and Welfare Helsinki, Finland
11	39 Sini Lähteenmäki	THE Biobank / The National Institute of Health and Welfare Helsink; Finland
114	40 Lotta Männikkö	THE Biobank / The National Institute of Health and Welfare Helsink; Finland
114	41 Regis Wong	THE Biobank / The National Institute of Health and Welfare Helsink; Finland
11	47 Regis Wolig	The brobank / The Parlohar Institute of Hearth and Wenate Heisniki, Finland
11	43 Registry Data Or	perations
11	44 Hannele Mattsson	THI Biohank / The National Institute of Health and Welfare Helsinki, Finland
114	45 Kati Kristiansson	THE Biobank / The National Institute of Health and Welfare Helsink; Finland
114	46 Susanna Lemmelä	Institute for Molecular Medicine Finland Hill IFF University of Helsinki, Finland
114	47 Sami Koskelainen	THI Biobank / The National Institute of Health and Welfare Helsinki Finland
114	48 Tero Hiekkalinna	THE Biobank / The National Institute of Health and Welfare Helsink; Finland
11	49 Teemu Paajanen	THE Biobank / The National Institute of Health and Welfare Helsink, Finland
11	50	The brobank / The Pational Institute of Health and Wenate Heisniki, Finland
11	50 51 Sequencing Infor	matics
11	57 Priit Palta	Institute for Molecular Medicine Finland, Hil IEF, University of Helsinki, Finland
11	53 Kalle Pärn	Institute for Molecular Medicine Finland, Hill IFE University of Helsinki Finland
11	54 Mart Kals	Institute for Molecular Medicine Finland, Hill IFE University of Helsinki Finland
11	55 Shuang Luo	Institute for Molecular Medicine Finland, HiLIFE, University of Helsinki, Finland
11	56 Vishal Sinha	Institute for Molecular Medicine Finland, Hill IFF, University of Helsinki, Finland
11	57	institute for Molecular Medicine i miland, inchi E, Omverský of Hershikk, i miland
11	58 Trajectory	
11	50 Taria Laitinen	Pirkanmaa Hospital District Tampere Finland
11	60 Mary Pat Reeve	Institute for Molecular Medicine Finland Hill IFF University of Helsinki Finland
11	61 Marjanna Niemi	Iniversity of Tampere Tampere Finland
11	62 Harri Siirtola	University of Tampere Tampere Finland
11	63 Javier Gracia-Tab	uenca University of Tampere, Tampere, Finland
11	64 Mika Helminen	University of Tampere, Tampere Finland
11	65 Tiina Luukkaala	University of Tampere, Tampere, Finland
11	66 Jida Vähätalo	Iniversity of Tampere, Tampere, Finland
11	67	Chryotsky of Fullpere, Fullpere, Fullpere,
11	67 68 Data protection (fficer
11	69 Tero Ivrhämä	Institute for Molecular Medicine Finland, Hil IEF, University of Helsinki, Finland
11'	70	institute for Molecular Medicine Finland, fillin E, Oniversity of Reisniki, Finland
11'	71 FINRR - Finnish	hiabank coonerative
11	72 Marco Hautalahti	
11'	73 Johanna Mäkelä	
11'	74 Laura Mustaniemi	
11'	75 Mirkka Koivusalo	
11'	76 Sarah Smith	
11'	77 Tom Southeringto	n
11	,, ion soundingto	11